Iatrogenic Creutzfeldt-Jakob disease - The waning of an era

被引:133
作者
Brown, Paul
Brandel, Jean-Philippe
Preese, Michael
Sato, Takeshi
机构
[1] Hop La Pitie Salpetriere, CJD Surveillance Unit, Paris, France
[2] Inst Child Hlth, London, England
关键词
D O I
10.1212/01.wnl.0000231528.65069.3f
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The outbreaks of iatrogenic Creutzfeldt - Jakob disease (CJD) from cadaveric human growth hormone and dura mater are winding down and, like the only other environmentally acquired form of CJD ( variant CJD due to infection with the agent of bovine spongiform encephalopathy), iatrogenic disease seems to have reached its high water mark during the 1990s. The total number of cases has reached 405, and the diminishing number of new cases is due to extremely long incubation periods from infections acquired before 1985 ( up to 23 years for dura mater and 36 years for growth hormone). Although no cases associated with surgical or other invasive procedures have been identified during the past several decades, the recent discovery of three transfusion-associated variant CJD infections has provoked new concerns about the possibility of further secondary transmissions from operative procedures as well as blood and tissue donations. Therefore, at least in those countries in which variant CJD has occurred, precautionary measures must continue for the indefinite future.
引用
收藏
页码:389 / 393
页数:5
相关论文
共 94 条
[1]  
ANDERSON J R, 1990, Neuropathology and Applied Neurobiology, V16, P543
[2]   Creutzfeldt-Jakob disease after extracranial dura mater embolization for a nasopharyngeal angiofibroma [J].
Antoine, JC ;
Michel, D ;
Bertholon, P ;
Mosnier, JF ;
Laplanche, JL ;
Beaudry, P ;
Hauw, JJ ;
Veyret, C .
NEUROLOGY, 1997, 48 (05) :1451-1453
[3]   CREUTZFELDT-JAKOB DISEASE IN A PHYSICIAN - A REVIEW OF THE DISORDER IN HEALTH-CARE WORKERS [J].
BERGER, JR ;
DAVID, NJ .
NEUROLOGY, 1993, 43 (01) :205-206
[4]  
BERNOULLI C, 1977, LANCET, V1, P478
[5]   Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK [J].
Brandel, JP ;
Preece, M ;
Brown, P ;
Croes, E ;
Laplanche, JL ;
Agid, Y ;
Will, R ;
Alpérovitch, A .
LANCET, 2003, 362 (9378) :128-130
[6]   Lyodura use and the risk of iatrogenic Creutzfeldt-Jakob disease in Australia [J].
Brooke, FJ ;
Boyd, A ;
Klug, GM ;
Masters, CL ;
Collins, SJ .
MEDICAL JOURNAL OF AUSTRALIA, 2004, 180 (04) :177-181
[7]  
Brown P, 1998, NATO ADV SCI I A-LIF, V295, P19
[8]   IATROGENIC CREUTZFELDT-JAKOB-DISEASE - AN EXAMPLE OF THE INTERPLAY BETWEEN ANCIENT GENES AND MODERN MEDICINE [J].
BROWN, P ;
CERVENAKOVA, L ;
GOLDFARB, LG ;
MCCOMBIE, WR ;
RUBENSTEIN, R ;
WILL, RG ;
POCCHIARI, M ;
MARTINEZLAGE, JF ;
SCALICI, C ;
MASULLO, C ;
GRAUPERA, G ;
LIGAN, J ;
GAJDUSEK, DC .
NEUROLOGY, 1994, 44 (02) :291-293
[9]   POTENTIAL EPIDEMIC OF CREUTZFELDT-JAKOB DISEASE FROM HUMAN GROWTH-HORMONE THERAPY [J].
BROWN, P ;
GAJDUSEK, DC ;
GIBBS, CJ ;
ASHER, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (12) :728-731
[10]  
BROWN P, 1988, PEDIATRICS, V81, P85